Abstract Number: 1842 • 2013 ACR/ARHP Annual Meeting
Pathophysiological Effects Of Free Fatty Acids On Key Cells Of Arthritis
Background/Purpose: Although obesity, a known risk factor for arthritic diseases, increases mechanical stress on joints, it appears not to be the only factor being responsible…Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…Abstract Number: 1844 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Sjogren’s Syndrome and Systemic Lupus Erythematosus Patients Have a Distinct Spectrum Of Serum Anticytokine Autoantibodies
Background/Purpose: Anticytokine autoantibodies are pathogenic in many hematologic, pulmonary and infectious diseases. However, the prevalence and significance of anticytokine autoantibodies in rheumatic conditions is poorly…Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…Abstract Number: 1846 • 2013 ACR/ARHP Annual Meeting
Mitochondrial Dysfunction Induces An Inflammatory, Tissue-Degrading, and Angiogenic Response In Normal Human Synoviocytes
Background/Purpose: Tissues affected with inflammatory arthritis (IA) are subjected to great levels of oxidative stress. Synoviocytes from IA patients present a higher rate of mitochondrial…Abstract Number: 1847 • 2013 ACR/ARHP Annual Meeting
Certolizumab-Pegol Induces Reverse Signaling Through Membrane TNF Via Calcineurin Activation In Human Monocytes. Relevance In Inflammation
Background/Purpose: Reverse signalling seems to play a role in the mode of action of anti-TNF-α agents but this pathway and its relevance are poorly understood.…Abstract Number: 1813 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Phosphodiesterase-5 inhibitors have been successfully used for the treatment of Raynaud’s phenomenon (RP) in patients with systemic sclerosis (SSc). However, no study has evaluated…Abstract Number: 1808 • 2013 ACR/ARHP Annual Meeting
Impact Of Baseline Disease Severity and Treatments On Outcomes In Clinical Trials Of SLE: Results From The Soccit Program
Background/Purpose: The Lupus Foundation of America Collective Data Analysis Initiative was established to evaluate SLE clinical trial design, using data collected from multiple studies. To…Abstract Number: 1809 • 2013 ACR/ARHP Annual Meeting
Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants
Background/Purpose: The BOLD study was designed to test the discriminatory capacity and safety of a trial design eliminating background immune suppressants (IS) in SLE patients…Abstract Number: 1810 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The New American College Of Rheumatology/European League Against Rheumatism Criteria For The Classification Of Systemic Sclerosis In The Canadian Scleroderma Research Group Cohort
Background/Purpose: New classification criteria for systemic sclerosis (SSc) have recently been developed. In this study, we aimed to assess the sensitivity of this classification in…Abstract Number: 1811 • 2013 ACR/ARHP Annual Meeting
Validation Of The ICD-CM-9 Code For Systemic Sclerosis Using Updated ACR/EULAR Classification Criteria
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease associated with substantial morbidity. Epidemiologic studies using large administrative databases often rely on the accuracy of…Abstract Number: 1812 • 2013 ACR/ARHP Annual Meeting
Adverse Events In Connective Tissue Disease-Associated Pulmonary Arterial Hypertension Compared To Idiopathic Pulmonary Arterial Hypertension
Background/Purpose: Whether the risk of treatment-related adverse events (AEs) in patients with pulmonary arterial hypertension (PAH) differs based on diagnosis, either connective tissue disease (CTD-PAH)…Abstract Number: 1814 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pulmonary Embolism and Deep Venous Thrombosis In Systemic Sclerosis: A Population-Based Cohort Study
Background/Purpose: Data on the risk of pulmonary embolism (PE) and deep venous thrombosis (DVT) in patients with systemic sclerosis (SSc) is lacking. To fill this…Abstract Number: 1815 • 2013 ACR/ARHP Annual Meeting
Asymmetric Dimethylarginine Levels In The Early Detection Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc), and alterations in nitric oxide (NO) metabolism and endothelial cell…Abstract Number: 1816 • 2013 ACR/ARHP Annual Meeting
Exercise Therapy Reduces Pain Sensitivity In Patients With Knee Osteoarthritis: A Randomized Controlled Trial
Background/Purpose: Exercise has beneficial effects on pain in patients with knee osteoarthritis (OA), yet the underlying analgesic mechanisms are ambiguous. A deeper understanding of the…